Leading in Academia, Industry, & the Clinic
Sam Rothstein, PhD
CEO and Cofounder
Sam Rothstein brings more than 12 years of experience in the design of complex drug products and has led $4 million of Small Business Innovation Research projects on their development. Prior to founding Duo Oncology, Dr. Rothstein began working at the interface of cancer immunotherapy and drug delivery as the CEO of Qrono Inc in 2017. Since joining industry in 2012, Dr. Rothstein has brought three complex drug products into IND-enabling studies. Dr. Rothstein holds chemical engineering degrees from Bucknell University and the University of Pittsburgh.
Katherine Eichinger, PharmD, PhD
Director of Operations
Katherine Eichinger is a licensed pharmacist with a master’s degree in clinical research and a doctorate in pharmaceutical science. Dr. Eichinger's experience bridges from fundamental bench research to clinical studies and includes operations experience from two major hospital systems. Her more than 10 years in preclinical research have led to eleven publications advancing science in drug pharmacology, immunology, and human disease. Her BS, MS, and PharmD degrees were conferred by the University of Michigan. Dr. Eichinger received her PhD from the University of Pittsburgh where she also completed a post-doctoral fellowship.
Jingjing Sun, PhD
Jingjing Sun has more than 10 years of experience developing nanoformulations for cancer therapy, including Duo Oncology's lead product. She is an inventor of 7 issued/pending patents in this field. She has also published one book chapter and 35 peer-reviewed papers in top journals. Dr. Sun is an aspiring Research Instructor in Department of Pharmaceutical Sciences, University of Pittsburgh where she also completed a post doc. She received her Ph.D. in Polymer Chemistry and Physics from the University of Chinese Academy of Sciences.
Board of Directors
Stanley Marks, MD
Stanley Marks, MD is the Chairman of UPMC's Hillman Cancer Center, the Chief of the Division of Hematology-Oncology at UPMC Shadyside, and a Clinical Professor of Medicine at the University of Pittsburgh. Dr. Marks is a world-recognized leader cancer research having served as President of The Leukemia & Lymphoma Society and on the board of directors of the American Cancer Society, among others. He is also a leading clinician and noted advocate for patients. He is consistent listed among the “Best Cancer Doctors in America” and his patients have founded the Dr. Stanley Marks Research Endowed fund at the Hillman Cancer Center which has raised $7 million for cancer research to date.
Song Li, MD, PhD
Dr. Song Li is a Professor & Director of Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy. Dr. Li’s major research area is drug and gene delivery. He is also interested in nuclear receptors and gene regulation. Dr. Li has broad knowledge in medicine, biology, and drug and gene delivery and is the author or co-author of over 180 peer-reviewed articles and book chapters. Dr. Li serves on the editorial boards of several journals and the review panels of NIH, DOD and other funding agencies.
Steve Thorne, PhD
Steve Thorne currently serves as Chief Scientific Officer of Kalivir and Western Oncolytics. He has many years of experience in the field of cancer immunotherapy, from discovery through clinical testing. As an entrepreneur, he has founded and co-founded several companies, including Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials, Western Oncolytics, Kalivir and Bioeclipse. Steve was previously a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London.
Jing Zhou Hou, MD, PhD
Dr. Hou is a hematological oncologist and clinical investigator at the UPMC Hillman Cancer Center. As a principal investigator, he has conducted more than 30 clinical trials from phase I to phase III investigating novel targeted, immune modulating agents or combinations with chemotherapy. Dr. Hou serves on the Lymphoma Pathway Committee and was co-chair from 2010-2015 at the ClinicalPath. Dr. Hou received his medical degree from Zhengzhou University and a PhD in Molecular and Cellular Biology from Tulane University. Dr. Hou completed an Internal Medicine residency at the Northeast Ohio Medical University, and a fellowship in Hematology and Medical Oncology at Stanford University.